Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

On November 5, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company’s investigational oral Bruton’s tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation abstract was released today by ASH (Free ASH Whitepaper) and highlights new and updated data in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with efficacy data reported for those previously treated with covalent BTK inhibitors (cBTKi). Results demonstrate continued evidence of durable clinical activity and favorable tolerability with bexobrutideg administered at the recommended Phase 2 dose of 600 mg once daily. Additional analyses, including data from BTK inhibitor-naïve and treatment naïve patients and efficacy in patients with high-risk molecular features, will be presented at the meeting.

"Patients with relapsed or refractory CLL/SLL continue to face significant challenges as resistance and intolerance emerge with currently available therapies," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics. "We are encouraged by the growing body of clinical evidence supporting bexobrutideg’s potential to address important unmet needs in patients at early as well as late stages of their therapeutic journeys. The updated data being presented at ASH (Free ASH Whitepaper) further underscore the differentiated mechanism of our BTK degrader, including its ability to target both wild-type and mutant forms of BTK, and reinforce our confidence in the ongoing development of bexobrutideg as a potential best-in-class therapy for patients with B-cell malignancies."

Poster Presentation Details
Title: New and updated efficacy and safety data on bexobrutideg (NX-5948), a novel BTK degrader, in patients with relapsed/refractory CLL/SLL and prior cBTKi exposure from an ongoing Phase 1a/b trial
Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Presenter: Nirav Shah, M.D., Medical College of Wisconsin
Session Date: December 13, 2026
Presentation Time: 12/13/2026 6:00:00 PM – 12/13/2026 8:00:00 PM
Room: Hall F

About Bexobrutideg (NX-5948)

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

​​​Bexobrutideg is currently being evaluated in a broad clinical development program in patients with CLL, including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

(Press release, Nurix Therapeutics, NOV 5, 2026, View Source [SID1234674371])

AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer

On November 5, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported the release of a new investor presentation, "The Ampligen Opportunity," highlighting the potential for Ampligen (rintatolimod) to complement emerging RAS-targeted therapies in pancreatic cancer, including Revolution Medicines’ Rasonque (daraxonrasib).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation examines recent advances in pancreatic cancer treatment and the scientific rationale for combining RAS inhibition with immune stimulation to potentially enhance and extend clinical benefit. It also highlights previously reported Ampligen clinical observations, the ongoing Phase 2 DURIPANC program and anticipated 2027 milestones.

AIM Chief Executive Officer Thomas K. Equels states: "Ampligen has been demonstrated to be a powerful innate immunomodulator with broad-spectrum anti-tumor proliferation effects, while the RAS-targeted therapy daraxonrasib represents a new and promising development which, I believe, will likely become a first-line therapy for pancreatic cancer. I see great potential in bringing the two together. While daraxonrasib targets the signaling pathways that drive tumor growth, Ampligen is designed to stimulate innate and adaptive immune responses, which helps set Ampligen apart among late-stage clinical trials for pancreatic cancer. We believe these potentially complementary mechanisms of action provide a compelling foundation for investigating how Ampligen might enhance and prolong the benefits of targeted RAS treatment, which is especially significant because of daraxonrasib’s potential to become the standard of care therapy for pancreatic cancer in the very near future."

Key Highlights from the Investor Presentation

Daraxonrasib’s Phase 3 Results and the Potential for Complementary Treatment Strategies

The presentation highlights results from the randomized Phase 3 RASolute 302 study evaluating daraxonrasib against investigators’ choice of chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma.

In the overall study population, daraxonrasib demonstrated:

Median overall survival of 13.2 months versus 6.7 months with chemotherapy (hazard ratio: 0.40).
Median progression-free survival of 7.2 months versus 3.6 months with chemotherapy (hazard ratio: 0.49).
These findings underscore the progress being made in RAS-targeted treatment and the opportunity to investigate strategies that may further extend disease control.

Complementary Mechanisms Support Further Investigation

Daraxonrasib inhibits RAS(ON) signaling involved in tumor growth, while Ampligen is an investigational Toll-like receptor 3 (TLR3) agonist designed to stimulate innate and adaptive immune responses.

Previously published research involving Ampligen has demonstrated immune modulation involving dendritic cells and T-cell responses. AIM believes these distinct mechanisms support further investigation of whether Ampligen could enhance anti-tumor immune activity alongside RAS inhibition.

The proposed combination remains investigational, and its safety, efficacy and potential to improve outcomes beyond daraxonrasib alone have not been established.

Previously Reported Ampligen Clinical Observations Provide an Encouraging Foundation

The presentation highlights findings from a Netherlands government-approved Named Patient Program evaluating Ampligen following FOLFIRINOX chemotherapy in patients with advanced pancreatic cancer.

In this nonrandomized program, 57 Ampligen-treated patients were compared with 27 historical controls. Exploratory findings included:

Median overall survival of 19.7 months versus 12.5 months in historical controls.
Median progression-free survival of 12.6 months versus 8.6 months in historical controls.
Median overall survival of 34.8 months in an Ampligen-treated subgroup with a baseline neutrophil-to-lymphocyte ratio of 4.5 or less, versus 19.3 months among Ampligen-treated patients with higher ratios.
DURIPANC Program Advancing Toward Key 2027 Clinical Milestones

AIM’s ongoing Phase 1/2 DURIPANC study is evaluating Ampligen in combination with durvalumab (Imfinzi) in patients with metastatic pancreatic cancer who achieved stable disease following FOLFIRINOX chemotherapy.

The study enrolled 28 patients across Phase 1 and Phase 2. The Phase 2 primary endpoint is clinical benefit rate at 24 weeks. To date, the clinical trial has met each milestone on schedule.

Previously reported interim findings include encouraging tolerability, with only three Grade 3 immune-related adverse events; consistently high patient-reported quality of life; and preliminary evidence of coordinated innate and adaptive immune activation.

AIM anticipates the following milestones:

Q1 2027: Phase 2 topline results evaluating clinical benefit rate at 24 weeks.
Q3 2027: Additional analyses of overall survival, progression-free survival, quality of life and immune responses.
These findings are expected to help inform future development opportunities, including the potential design of a pivotal Phase 3 trial.

Exploring the Potential to Extend RAS-Targeted Treatment Benefits

The presentation also outlines a proposed development strategy to investigate whether adding Ampligen to ongoing daraxonrasib treatment, or as a post-daraxonrasib maintenance therapy, could strengthen anti-tumor immune responses and potentially extend disease control.

Potential evaluations include safety, biological activity, treatment timing, progression-free survival and duration of response. This proposed strategy is not an established clinical trial protocol, and additional research would be required to evaluate the combination.

Positioning Ampligen for the Evolving Pancreatic Cancer Treatment Landscape

As RAS-targeted therapies continue to advance, AIM believes Ampligen’s immunomodulatory mechanism and existing clinical observations provide a foundation for exploring complementary treatment strategies.

With anticipated DURIPANC milestones in 2027, the Company remains focused on generating additional clinical evidence while evaluating opportunities to expand Ampligen’s potential role in pancreatic cancer treatment.

The Company’s new investor presentation, "The Ampligen Opportunity," is available here.

About Ampligen

Ampligen (rintatolimod) is an investigational immunomodulatory drug that acts through Toll-like receptor 3 (TLR3) signaling. It is being investigated for its potential to stimulate innate and adaptive immune responses across multiple disease settings, including cancer. In pancreatic cancer, research has demonstrated immune modulation involving dendritic-cell-mediated T-cell responses. Ampligen is not approved by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.

(Press release, AIM ImmunoTech, NOV 5, 2026, View Source [SID1234674296])

Intellia Therapeutics Announces Third Quarter 2026 Financial Results
and Business Updates

On November 5, 2026 Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, reported business updates and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead," said John Leonard, M.D., Intellia President and Chief Executive Officer. "We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy. As a one-time treatment, we believe it could transform the HAE treatment paradigm while also delivering significant value to patients, physicians, payers and the overall healthcare system."

Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks and the need for lifelong treatment.

•
In September, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. Additionally, FDA advised that it is not currently planning to hold an advisory committee to discuss the application. If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
•
Intellia significantly advanced its launch readiness in recent months, completing the deployment of its field organization and deepening its engagement with HAE treatment centers and payers in preparation for a planned commercial launch in the first quarter of 2027.

Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis

Nex-z is an in vivo CRISPR-based therapeutic candidate designed to inactivate the TTR gene in the liver, thereby preventing the production of transthyretin (TTR) protein. Nex-z offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment. Intellia leads the development and commercialization of nex-z in collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron).

•
Intellia has made significant progress advancing enrollment in its MAGNITUDE Phase 3 clinical trial in ATTR amyloidosis with cardiomyopathy (ATTR-CM).
•
During the third quarter, the company completed enrollment in its MAGNITUDE-2 Phase 3 clinical trial in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), exceeding its targeted randomization of 60 patients.
•
During the third quarter, Intellia began providing investigators with human leukocyte antigen (HLA) genotyping results for patients enrolled or entering screening in the ongoing nex-z Phase 3 trials.

Other Recent Updates

•
In September, Intellia entered into a non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm, for up to $400 million. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including the planned U.S. approval and commercial launch of lonvo-z in HAE.
•
In October, the company announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, she is leading the company’s translational, development, regulatory and medical affairs functions.

Upcoming Events

The company will participate in the following upcoming events:

•
November 6-9 – American Heart Association Scientific Sessions in Chicago, IL
•
November 12 – Intellia investor webcast regarding lonvo-z in HAE
•
November 12-16 – American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, AZ

•
November 15-18 – International Symposium on Amyloidosis in Montevideo, Uruguay
•
November 17 – Jefferies London Healthcare Conference in London, England
•
December 7-9 – 23rd Global Cardiovascular Clinical Trialists Forum in Washington, D.C.

Third Quarter 2026 Financial Results

•
Cash Position: Cash, cash equivalents and marketable securities were $614.8 million as of September 30, 2026, compared to $605.1 million as of December 31, 2025. The company’s existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027. This guidance excludes all potential commercial revenues from lonvo-z and potential future funding from the company’s term loan facility.
•
Collaboration Revenue: Collaboration revenue was $7.2 million for the third quarter of 2026, compared to $13.8 million for the third quarter of 2025. The decrease is primarily due to a reduction in revenue from Regeneron.
•
R&D Expenses: Research and development (R&D) expenses were $83.3 million for the third quarter of 2026, compared to $94.7 million for the third quarter of 2025. The decrease was primarily driven by lower external costs related to lonvo-z, lower stock-based compensation and lower research materials and contracted services costs, partially offset by higher headcount-related expenses. Stock-based compensation expense included in R&D expenses was $7.4 million for the third quarter of 2026.
•
G&A Expenses: General and administrative (G&A) expenses were $46.1 million for the third quarter of 2026, compared to $30.5 million for the third quarter of 2025. The increase was primarily driven by consulting costs associated with the continued buildout of the company’s commercial infrastructure and higher legal, facility-related and compensation expenses. Stock-based compensation expense included in G&A expenses was $7.0 million for the third quarter of 2026.
•
Net Loss: Net loss was $127.5 million for the third quarter of 2026, compared to $101.3 million for the third quarter of 2025. Net loss for the third quarters of 2026 and 2025 included an unrealized loss of $10.4 million and an unrealized gain of $3.4 million, respectively, due to changes in the fair value of investments.

(Press release, Intellia, NOV 5, 2026, View Source [SID1234674312])

Step Pharma to present data from ongoing phase 2 clinical trial of dencatistat in essential thrombocythaemia at 68th ASH Annual Meeting

On November 5, 2026 Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, reported that an oral presentation disclosing the first preliminary data from its ongoing, open-label phase 2 VECTRA trial of dencatistat for high risk essential thrombocythaemia (ET) will be delivered at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place in New Orleans, Louisiana from 12–15 December 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ET is a rare blood cancer characterised by the overproduction of platelets and increased risk of thrombosis that can lead to serious complications such as stroke or heart attack. The VECTRA trial is evaluating the safety, tolerability and efficacy of dencatistat, the Company’s first-in-class, highly selective, oral CTPS1 inhibitor, in up to 50 participants with high-risk ET across sites in the US, EU and UK. The trial’s primary endpoints are efficacy, safety, and tolerability. Secondary endpoints include durability of haematologic response and rates of thrombosis, haemorrhage, and disease transformation.

As of 21 July 2026, 10 out of 12 (83%) evaluable participants achieved platelet normalisation, and all achieved a platelet count of <600 ×10⁹/L, with a median maximal platelet reduction of 76% (22–86%) and no thromboembolic events occurring. A favourable tolerability profile was observed with nine participants (64%) having treatment related adverse events, predominantly anaemia and nausea. Further data will be presented at the meeting.

Oral Presentation Details:

Presentation title: A phase 2 study of dencatistat, an oral CTP synthase 1 inhibitor, for the treatment of high risk essential thrombocythemia; preliminary data from the VECTRA study.

Session: 634: Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs

Date and time: Monday 14 December 2026, 4:00 PM to 4:15 PM CT

Presenter: Michael Loschi MD PhD

Location: Hall B, Ernest N. Morial Convention Center (MCCNO), New Orleans, Louisiana

Further details of the VECTRA trial can be found on ClinicalTrials.gov under the identifier NCT06786234.

(Press release, Step Pharma, NOV 5, 2026, View Source [SID1234674328])

FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents

On November 5, 2026 FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported that the European Patent Office has granted European Patent No. EP 4454709, titled "Fibroblast Delivery of Tumor Inhibitory Agents." The patent covers methods of preparing fibroblasts as anti-cancer delivery compositions by modifying the cells to improve their ability to home to cancer cells and loading them with one or more tumor inhibitory agents, including an oncolytic virus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cancer is still one of the most difficult diseases in medicine. Many of the most promising anti-cancer agents, including oncolytic viruses, cytokines, and suicide genes, do their best work inside a tumor. The hard part is getting enough of them there without harming healthy tissue. Fibroblasts have a natural tendency to migrate toward tumors, where they are recruited into the surrounding stroma. The patent builds on that tendency and turns the fibroblast into a delivery vehicle.

The newly granted patent describes methods in which fibroblasts are modified to enhance their homing activity toward cancer cells or cancerous tissue. The claimed tumor inhibitory agent comprises an oncolytic virus, such as vaccinia virus. In data described in the patent, fibroblasts carrying Newcastle disease virus significantly inhibited tumor growth in a mouse melanoma model, while the virus given on its own, even at high doses, did not affect tumor growth.

Coverage and strength of the patent include:

The independent claim covers the core method of preparing tumor-homing fibroblasts loaded with an oncolytic virus and conditioned under hypoxia, whether the homing step is performed before, after, or at the same time as the loading step. Other claims add specific homing receptors (CXCR4, CXCL16, and CCL9), vaccinia virus as the oncolytic virus, and additional payloads delivered by vector, including TNF-alpha, TRAIL, suicide genes, the interleukins IL-2, IL-12, IL-18, and IL-23, interferons, and bispecific antibodies.

Additional claims cover modified fibroblasts for use in treating cancer in individuals who have cancer or are at risk for it, alongside surgery, chemotherapy, radiation, hormone therapy, or immunotherapy. The patent protects the engineered cells as they would be used in a patient, not only the way they are made.
"We filed the first application behind this patent when very few people were thinking about fibroblasts as a way to carry a cancer-killing virus into a tumor," said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. "Fibroblasts are abundant, they are easy to grow, and they already know how to find a tumor. Our job is to give them something useful to carry when they get there. This patent gives us a long runway in Europe to do that work. Cancer is a long game, and we are building for it."

About the Technology

Fibroblasts are the most common cell type found in connective tissue and play a central role in tissue repair. Tumors actively recruit fibroblasts into the surrounding stroma, and FibroBiologics’ patented approach puts that behavior to work. The cells are modified in culture to strengthen their homing activity toward cancer cells, conditioned under hypoxia, and loaded with one or more tumor inhibitory agents, such as an oncolytic virus or a vector encoding an anti-cancer protein. Once administered, the fibroblasts are intended to carry their payload into the tumor and release it where it is needed, with the goal of concentrating the treatment at the cancer and limiting exposure to healthy tissue.

(Press release, FibroBiologics, NOV 5, 2026, View Source [SID1234674356])